OncoMed Pharmaceuticals, Inc. (OMED) is an early developmental-stage biotechnology company focused on discovering and developing first-in-class monoclonal antibody ("MAB") therapeutics targeting cancer stem cells ("CSCs"). Based in Redwood City, California, OMED recently went public in July. The company sold 5,520,000 shares for $17.00 per share and received net cash proceeds of $82.7MM.
In normal tissue development, tissues are maintained over the long term by a small population of normal stem cells, which have self-renewal capabilities, or the ability to proliferate indefinitely while maintaining pluripotency. Similarly, it has been found that cancer cells can inappropriately activate self-renewal pathways, enabling a small set of cancer stem cells to exhibit properties similar to normal stem cells, but without the proper...
Only subscribers can access this article, which is part of the PRO research library covering 3,589 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: